Stifel analysts began coverage of Edgewise Therapeutics (NASDAQ:EWTX), currently valued at $2.6 billion, with a Hold rating and set a price target of $30.00. According to InvestingPro data, the stock ...
Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
A pilot study in 19 LGMD patients and one with Becker MD found low-dose prednisone helped lower markers of muscle damage and ...
Dillon, left, as Supergirl, Dominique Dickson as Wonder Mom and Dason as Raphael the Ninja Turtle got into the spirit of ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid ...
Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, ...
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
Muscular Dystrophy (MD) is a genetic condition causing progressive muscle weakness and complications in vital organs. Early ...
Phoenix Pinnacle will never forget the impact the kid in the wheelchair had during its greatest stretch in Arizona high ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback